- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02856178
Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients (SAFEGUARD)
An Open Label Phase IIa Clinical Study to Evaluate the Safety and Pharmacokinetics of Intravenous and Oral F901318 (Combined With Caspofungin) for Antifungal Prophylaxis in Patients Undergoing Chemotherapy for Acute Myeloid Leukaemia
Study Overview
Status
Intervention / Treatment
Detailed Description
F901318 has potent in vitro efficacy against Aspergillus spp. including azole-resistant strains and consistent efficacy in in vivo mouse models of infection. F901318 is active by both oral and intravenous routes of administration in preclinical efficacy studies.
Non-clinical studies and phase I clinical trials show that F901318 has a good overall safety profile and limited potential for drug-drug interactions. F901318 exhibits a highly promising profile which can potentially address the critical treatment requirements for invasive Aspergillus infections in a changing clinical environment in which new classes of antifungals are needed.
This phase IIa study aims to confirm PK and safety information of F901318 from phase I and bridge them to a neutropenic AML patient population, which represents the main population for future efficacy trials. Coadministration of caspofungin will allow recognizing potential factors of suboptimal F901318 exposure without the risk of fatal disseminating infection.
Study Type
Phase
- Phase 2
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients diagnosed with AML and entering treatment of chemotherapy.
- Patients are expected to be neutropenic (< 500 ANC/μl) for > 10 days.
- Provision of written informed consent prior to any study specific procedures.
- Ability and willingness to comply with the protocol.
- Patients aged over 18 years.
- Patient has or will receive within 2 days a multi-lumen central venous catheter as standard of care.
Exclusion Criteria:
- Documented lung infiltrate at screening.
- Documented serum GMI ≥0.5 at screening
- Current IFD or prior history of IFD or patients who received systemic antifungal therapy for proven or probable IFD in the last 12 months.
- Patients who received any systemic antifungal therapy for more than 72 hours immediately prior to first administration of study medication. Echinocandins and topical polyenes or nystatin are acceptable. Posaconazole and other azoles have to be discontinued at least 3 days before start of F901318.
- Concomitant exposure to phenobarbital and long acting barbiturates, triazolam, carbamazepine, phenytoin, pimozide, cisapride, efavirenz, ritonavir, rifabutin, rifampicin, ergot alkaloids (ergotamine, dihydroergotamin), ibrutinib, idelalisib, vinca alkaloids, digoxin, dofetilide, quinidine, St. John´s wort, everolimus, sirolimus, astemizole, terfenadine, methadone, alfentanil, fentanyl and other structurally related opiates, warfarin.
- Documented prolongation of the QTc interval (>450 ms).
- Concomitant medication that prolongs QT interval (except for cytostatic drugs used during chemotherapy, such as mitoxantrone).
- Any other concomitant medical condition that, in the opinion of the investigator, may be an unacceptable additional risk to the patient should he/she participate in the study.
- History of convulsion.
- Female patients only: Positive result of pregnancy test or breastfeeding.
- Female patients of childbearing potential who do not agree to not have sexual intercourse during the study or who do not use or do not agree to use appropriate contraceptive methods (prior to and during the study, including 14 days after the last dose of study therapy) as defined in ICH guideline M3(R2) on non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals (EMA/CPMP/ICH/286/1995). Hormonal contraception alone is not considered appropriate.
- Known hypersensitivity to any component of the study medication.
- A history of additional risk factors for Torsade de pointes (e.g., heart failure, hypokalaemia, cardiomyopathy, sinus bradycardia, symptomatic arrhythmias, family history of long QT Syndrome).
- Patient has had acute hepatitis in the prior 6 months, chronic hepatitis, cirrhosis (any Child-Pugh class), acute hepatic failure, or acute decompensation of chronic hepatic failure
- Presence of hepatic disease as indicated by aspartate aminotransferase (AST) or alanine transaminase (ALT)>3 × upper limit of normal (ULN) at Screening. Patients with AST and/or ALT >3 × ULN and <5 × ULN are eligible if these elevations are acute, not accompanied by a total bilirubin ≥2xULN and documented by the investigator as being directly related to an infectious process being treated. During the clinical study, the investigator is responsible for, without delay, determining whether the patient meets potential Hy's law criteria (according to FDA [28]).
- Patient has a total bilirubin >3 × ULN, unless isolated hyperbilirubinemia is directly related to an acute infection or due to known Gilbert's disease.
- Calculated creatinine clearance (CrCl) < 50 mL/minute.
- Medical history of oliguria (< 20 mL/h) unresponsive to fluid challenge.
- Suspected other or additional cause for neutropenia or immunosuppression (other than AML or myelodysplastic syndrome).
- Any other medical condition which may affect the clinical evaluability of the patient.
- Patients previously enrolled in this study.
- Patient has participated or intends to participate in any other clinical study that involves the administration of an investigational medication at the time of presentation, during the course of the study, or during the 30 days prior to study start. New combinations of labelled substances for chemotherapy are allowed.
- Chronic ocular disease.
- Contact lens use intended during study treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: F901318 + Caspofungin
Patients will receive F901318 intravenously, starting 24 - 72 h after last chemotherapy infusion:
Concomitant medication: For Candida prophylaxis, concomitant caspofungin will be administered from the 4th day of chemotherapy until end of neutropenia:
All patients will undergo chemotherapy for acute leukaemia according to local clinical standard. |
F901318 treatment starting after completion of chemotherapy.
Max. 14 days of intravenous F901318 b.i.d.
treatment, followed by one oral dose of F901318.
Loading doses 4 mg/kg b.i.d.
, maintenance doses 2 mg/kg b.i.d.
Intravenous Caspofungin treatment starting during chemotherapy for concomitant prophylaxis of fungal infection.
Loading dose 70 mg q.d., maintenance doses 50 mg q.d.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Collection of adverse events, results of physical examination, vital signs, ECGs, and laboratory assessments during F901318 intravenous infusion and oral formulation.
Time Frame: 57 days
|
57 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Concentration-time profile of F901318 following i.v. administration
Time Frame: 14 days
|
F901318 trough level assessment for 14 days once per day.
On three of these 14 days additional samples for determination of plasma concentration of F901318 will be collected.
|
14 days
|
Measured concentration of F901318 at the end of an i.v. dosing interval at steady state (Ctrough)
Time Frame: 14 days
|
14 days
|
|
Minimum observed plasma or serum, concentration of F901318 during an i.v. dosing interval at steady state (Cmin, ss)
Time Frame: 14 days
|
14 days
|
|
Maximum observed plasma or serum, concentration of F901318 during an i.v. dosing interval at steady state (Cmax, ss)
Time Frame: 14 days
|
14 days
|
|
Average plasma or serum concentration of F901318 at steady state after i.v. administration (Cav,ss)
Time Frame: 14 days
|
14 days
|
|
Area under the concentration-time curve during a F901318 i.v. dosing interval at steady state calculated by trapezoidal rule (AUCT,ss)
Time Frame: 14 days
|
14 days
|
|
Area under the concentration vs. time curve from point zero up to the end of infusion of F901318 (AUC(0-T))
Time Frame: 14 days
|
T: total time of infusion
|
14 days
|
Area under the concentration vs. time curve from time point zero up to the time point t (AUC(0-t)) for F901318 after i.v. administration
Time Frame: 14 days
|
14 days
|
|
Area under the concentration vs. time curve from time point zero up to the last measured concentration of F901318 above LOQ (AUC(0-t_last)) after i.v. administration
Time Frame: 14 days
|
14 days
|
|
Apparent terminal half-life (t1/2) of F901318 after i.v. administration
Time Frame: 14 days
|
14 days
|
|
Terminal rate constant (λz) of F901318 after i.v. administration
Time Frame: 14 days
|
14 days
|
|
Apparent clearance (Cl) of F901318 after i.v. administration
Time Frame: 14 days
|
14 days
|
|
Plasma concentration of F901318 after oral application
Time Frame: 1 day
|
Measurement 2h, 4h, 12h and 24h after oral intake of F901318
|
1 day
|
Number of patients developing an possible/probable/proven invasive fungal disease (IFD) according to EORTC/MSG criteria
Time Frame: 57 days
|
Patients galactomannan index and body temperature will be assessed regularly.
If it is clinically indicated the patients will undergo a CT, which will be checked for infiltrations.
If infiltrations are detected the patients will undergo a bronchoalveolar lavage, the result of which will be used to analyse BAL GMI, to grow a microbiological culture, to perform histology and perform an Aspergillus PCR.
On the basis of the available data for each patient the scientific advisory committee will assess the number of patients suffering from a possible/probable or proven IFD.
|
57 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Oliver Cornely, PhD, MD, University Hospital Cologne
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lung Diseases
- Bacterial Infections and Mycoses
- Mycoses
- Invasive Fungal Infections
- Lung Diseases, Fungal
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Aspergillosis
- Pulmonary Aspergillosis
- Invasive Pulmonary Aspergillosis
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antifungal Agents
- Caspofungin
- Olorofim
Other Study ID Numbers
- F901318C20
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Kronos BioActive, not recruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States, Spain
-
Massachusetts General HospitalExelixisCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
Clinical Trials on F901318
-
F2G Biotech GmbHQuotient ClinicalCompleted
-
F2G Biotech GmbHSimbec-Orion GroupCompleted
-
F2G Biotech GmbHQuotient ClinicalWithdrawn
-
F2G Biotech GmbHCovanceCompletedInvasive AspergillosisUnited Kingdom
-
F2G Biotech GmbHCompletedHepatic ImpairmentUnited States
-
F2G Biotech GmbHCovanceCompleted
-
F2G Biotech GmbHPRA Health SciencesCompletedInvasive Fungal InfectionsNetherlands
-
F2G Biotech GmbHHammersmith Medicines ResearchCompleted
-
F2G Biotech GmbHCompletedRenal ImpairmentUnited States
-
F2G Biotech GmbHQuotient ClinicalWithdrawnInvasive Aspergillosis